Answers are grounded in this paper and cite their sources.
BACKGROUND: Angiogenesis is essential for tumour growth and development and since the pioneering work of Judah Folkman several anti-angiogenic strategies have now been successfully employed. OBJECTIVE: This article aims to present a detailed review of current knowledge of the main pathways involved in angiogenesis, the strategies employed for inhibition and the current status of angiogenesis inhibitors in therapeutic use. METHODS: A systematic review of the literature was undertaken including angiogenesis in cancer and angiogenesis inhibitors in pre-clinical and clinical trials. CONCLUSION: While angiogenic inhibitors are now in clinical use, their limited benefits mean we must urgently develop strategies to improve the efficacy of this approach.
No takes yet. Share an insight, caveat, or question.
Staton et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: